Biogen Multiple Sclerosis Pregnancy Exposure Registry

Multiple Sclerosis Clinical Trial

Official title:

Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01911767
• Other study ID #: 109MS402
• Status: Completed
• Start date: October 30, 2013
• Est. completion date: February 10, 2022

Study information

• Verified date: June 2022
• Source: Biogen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The primary objective of the study is to prospectively evaluate pregnancy outcomes in women with multiple sclerosis who were exposed to a Registry-specified Biogen Multiple Sclerosis product during the eligibility window for that product. The Registry-specified Biogen MS products being studied are dimethyl fumarate, and Pegylated human interferon beta-1a. The secondary objective of the study is to prospectively evaluate pregnancy outcomes in women with MS who were unexposed to disease-modifying therapies (DMTs).

Description:

The Biogen Multiple Sclerosis Pregnancy Exposure Registry is a prospective, observational registry designed to evaluate pregnancy outcomes in women with multiple sclerosis (MS) who were exposed to a Registry-specified Biogen Multiple Sclerosis product during the eligibility window for that product. Women of childbearing potential are a considerable segment of the patient population affected by MS and are likely to be exposed to a Registry-specified Biogen MS product around the time of conception and during pregnancy. Biogen completed pregnancy registries for Avonex and Tysabri; however, formal studies in pregnant women have not been conducted. Therefore, it is important to evaluate, in a global Pregnancy Registry, how exposure to a marketed Biogen MS product specified in this Pregnancy Registry may affect pregnancy and infant outcomes. Data will be collected on prospective pregnancies (i.e. enrollment prior to knowledge of outcome) at time of enrollment, 6 to 7 months gestation, and approximately 4,12, and 52 weeks after estimated date of delivery. The prevalence of spontaneous abortions, birth defects, and other pregnancy and infant outcomes will be calculated and compared to background rates from external sources such as the European Surveillance of Congenital Anomalies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 408
• Est. completion date: February 10, 2022
• Est. primary completion date: February 10, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Key Inclusion Criteria:

• Patient consent

• Patient has a diagnosis of MS.

• Documentation that the patient was exposed to a Registry-specified Biogen MS product during the eligibility window for that product.

• DMF: Exposure since the first day of her last menstrual period (LMP) prior to conception or at any time during pregnancy.

• Peginterferon beta-1a: Exposure since 17 days prior to the first day of her LMP prior to conception or at any time during pregnancy.

• DMT unexposed pregnancy cohort: Never received DMT therapy

• Patient agrees to sign the Release of Medical Information Form, thereby permitting the Registry to contact her health care provider (HCP(s)) and the pediatric HCP for medical information.

Key Exclusion Criteria:

• The outcome of the pregnancy (i.e., pregnancy loss or live birth) must not be known at the time of enrollment.

• Initial maternal health assessment upon confirmation of pregnancy does not preclude participation in the Registry unless a patient tests positive for a medical condition associated with negative pregnancy outcomes (e.g., toxoplasmosis screen and syphilis [venereal disease research laboratory test and rapid plasma reagin test] blood screen) in the opinion of the healthcare provider (HCP).

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Related Conditions & MeSH terms

• Exposure During Pregnancy
• Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• Dimethyl fumarate
Administered as specified in treatment arm.
• Peginterferon beta-1a
Administered as specified in treatment arm.

Locations

Country	Name	City	State
Australia	Research Site	Box Hill	Victoria
Canada	Research Site	Cambridge	Massachusetts
France	Research Site	Bron CEDEX	Cedex
Germany	Research Site	Bochum	Nordrhein Wesfalen
Ireland	Research Site	Dublin
Italy	Research Site	Firenze
Italy	Research Site	Genova
Italy	Research Site	Milano
Italy	Research Site	Palermo
Italy	Research Site	Roma
Poland	Research Site	Bialystok
Spain	Research Site	Madrid
Spain	Research Site	Malaga
United Kingdom	Research Site	Salford	Greater Manchester
United States	Research Site	Cambridge	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Biogen

Countries where clinical trial is conducted

United States,  Australia,  Canada,  France,  Germany,  Ireland,  Italy,  Poland,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pregnancy Loss	Elective or therapeutic pregnancy terminations (any induced or voluntary fetal loss during pregnancy); Spontaneous abortions (<22 weeks of gestation); Fetal death, including stillbirths (fetuses born dead at >=22 weeks of gestation), which will be further classified as follows: early fetal loss (fetal death occurring at >=22 weeks but <28 weeks of gestation); late fetal loss (occurring at >=28 weeks of gestation)	During pregnancy up to 52 weeks post-delivery
Primary	Live Birth	Premature birth (delivered <37 weeks); Full-term birth (delivered >=37 weeks)	During pregnancy up to 52 Weeks Post-Delivery